Skip to main content
. 2020 Sep 16;39(2):469–476. doi: 10.1007/s10637-020-01001-5

Table 3.

Best overall response

Crenigacestat 25 mg (n = 4) Crenigacestat 50 mg (n = 7)
Best overall response
Complete response (CR) 0 0
Partial response (PR) 0 0
Stable disease (SD) 0 1 (14.3)
Progressive disease 4 (100.0) 6 (85.7)
Disease control rate (CR/PR/SD) 0 1 (14.3)

Data reported as n (%)

Abbreviations: n number of patients